Mizuho Maintains Outperform on Minimed Group, Raises Price Target to $26

Benzinga Newsdesk www.benzinga.com Positive 93.1%

Neg 0% Neu 0% Pos 93.1%

Mizuho analyst Anthony Petrone maintains Minimed Group (NASDAQ:MMED) with a Outperform and raises the price target from $21 to $26.